Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084214 · ClinicalTrials.gov registry record · Phase 1
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT00084214: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT00084214 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 103 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084214, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
Interventions
- DRUG Paclitaxel
- DRUG STA-4783
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2004-05 |
| Phase | Phase 1 |
What the finished NCT00084214 record still lists
NCT00084214 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% higher).
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00084214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00084214 about?
NCT00084214 is a clinical study titled "STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma". This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
What is the current status of trial NCT00084214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2004-05.
What interventions are being tested in trial NCT00084214?
The interventions under investigation include: Paclitaxel (DRUG), STA-4783 (DRUG).
Who is sponsoring clinical trial NCT00084214?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00084214's enrollment target sits among peer trials
103 541st of 2000 higher than 1,458 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia